Adial Pharmaceuticals (NASDAQ: ADIL)

Adial Pharmaceuticals (NASDAQ: ADIL) Employee Directory

Pharmaceutical ManufacturingUnited States11-50 Employees

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) and is currently being investigated in the Company’s landmark ONWARD™ Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company’s proprietary companion diagnostic genetic test. A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance), and no overt safety concerns (there were no statistically significant serious adverse events reported). AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. The Company is also developing adenosine analogs for the treatment of pain and other disorders.

Find Adial Pharmaceuticals (NASDAQ: ADIL) employees' phone numbers or email addresses

Adial Pharmaceuticals (NASDAQ: ADIL) Global Highlights

Location
Employees

North America
15

Minus sign iconPlus sign icon
  • United States Of America
    15

Asia
3

Minus sign iconPlus sign icon
  • India
    2
  • Pakistan
    1

Adial Pharmaceuticals (NASDAQ: ADIL)'s Leadership

  • Stylized image of a person
    C. C.
    Chief Executive Officer
    Phone icon
  • Stylized image of a person
    W. S.
    Chief Executive Officer
    Phone icon
  • Stylized image of a person
    T. D. G.
    Chief Operating Officer
    Phone icon
  • Stylized image of a person
    J. R. M.
    Chief Legal Officer/General Counsel
    Phone icon
  • Stylized image of a person
    C. C.
    Chief Operating Officer
    Phone icon
  • Stylized image of a person
    M. P.
    Chief Strategy Officer
    Phone icon
  • Stylized image of a person
    B. J.
    Founder & Cmo, Adial
    Phone icon
  • Stylized image of a person
    A. T.
    Vp Corporate Development And Special Projects
    Phone icon

Contact profiles from Adial Pharmaceuticals (NASDAQ: ADIL)

Name
Title
Contact Info
Location
Last Update
  • Stylized image of a person
    B. J.
    Founder & Cmo, Adial
    Phone icon
    United StatesFlorida
    Nov 12, 2025
  • Stylized image of a person
    C. C.
    Chief Executive Officer
    Phone icon
    United StatesGeorgia
    Nov 11, 2025
  • Stylized image of a person
    T. D. G.
    Chief Operating Officer
    Phone icon
    United StatesVirginia
    Sep 19, 2025
  • Stylized image of a person
    J. R. M.
    Chief Legal Officer/General Counsel
    Phone icon
    United StatesVirginia
    Oct 23, 2025
  • Stylized image of a person
    C. C.
    Chief Operating Officer
    Phone icon
    Mar 06, 2025
  • Stylized image of a person
    M. P.
    Chief Strategy Officer
    Phone icon
    Oct 18, 2023
  • Stylized image of a person
    W. S.
    Chief Executive Officer
    Phone icon
    Jun 25, 2025
  • Stylized image of a person
    A. T.
    Vp Corporate Development And Special Projects
    Phone icon
    United StatesMaryland
    Oct 26, 2025
  • Stylized image of a person
    C. F.
    Controller
    Phone icon
    Sep 27, 2023
  • Stylized image of a person
    A. S.
    Consultant
    Phone icon
    United States
    Oct 17, 2024

Frequently Asked Questions

What is Adial Pharmaceuticals (NASDAQ: ADIL) known for?

Minus sign iconPlus sign icon
Adial Pharmaceuticals (NASDAQ: ADIL) was founded in 2010 operates in the Pharmaceutical Manufacturing industry. The company's main headquarters is located in 4870 Sadler Rd, Suite 300 Glen Allen, Virginia 23060, US; you can contact the main corporate office by phone at . Explore Adial Pharmaceuticals (NASDAQ: ADIL)'s company overview page for more information.

What is Adial Pharmaceuticals (NASDAQ: ADIL)'s most common email format?

Minus sign iconPlus sign icon
Adial Pharmaceuticals (NASDAQ: ADIL) employees' email format typically follows the pattern of . Trying to find reliable and up-to-date employee contact data? Find more Adial Pharmaceuticals (NASDAQ: ADIL) email formats with LeadIQ.

How many employees does Adial Pharmaceuticals (NASDAQ: ADIL) have currently?

Minus sign iconPlus sign icon
Adial Pharmaceuticals (NASDAQ: ADIL) has approximately 15 employees as of October 2025. These team members are located across 2 continents, including North AmericaAsia.

Who are Adial Pharmaceuticals (NASDAQ: ADIL)'s key employees and leadership?

Minus sign iconPlus sign icon

As of October 2025, Adial Pharmaceuticals (NASDAQ: ADIL)'s key employees include:

  • Chief Executive Officer: C. C.
  • Chief Executive Officer: W. S.
  • Chief Operating Officer: T. D. G.
  • Chief Legal Officer/General Counsel: J. R. M.
  • Chief Operating Officer: C. C.

Looking for contact data? Unlock accurate emails and phone numbers for your ideal prospects with LeadIQ.

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.